Stock Taper
OPPORTUNITY RADAR
SCREENER
COMPARE ANY 2 STOCKS
Pricing
Log In
SIGN UP
EARNINGS CALL ARCHIVE
1 CALL ON FILE
IBRX
— ImmunityBio, Inc.
NASDAQ
FULL STOCK PAGE →
Q4 2025 Earnings Call Summary
MAR 3, 2026
REVENUE
$38.3M
+19.4%
NET MARGIN
-161.8%
+48.0 PTS
EPS
-$0.06
+11.8%
FREE CASH FLOW
-$71.7M
-2.8%
No summary has been written for this call yet.
← NEWER CALL
CALL 1 OF 1
OLDER CALL →